Peter J. Goebell

2.5k total citations
62 papers, 1.3k citations indexed

About

Peter J. Goebell is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Peter J. Goebell has authored 62 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Surgery, 20 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Peter J. Goebell's work include Bladder and Urothelial Cancer Treatments (41 papers), Urinary and Genital Oncology Studies (25 papers) and Renal cell carcinoma treatment (10 papers). Peter J. Goebell is often cited by papers focused on Bladder and Urothelial Cancer Treatments (41 papers), Urinary and Genital Oncology Studies (25 papers) and Renal cell carcinoma treatment (10 papers). Peter J. Goebell collaborates with scholars based in Germany, United States and Canada. Peter J. Goebell's co-authors include Margaret A. Knowles, Bernd J. Schmitz‐Dräger, Yves Fradet, Susan Groshen, Thomas Ebert, Richard J. Côté, Sunanda Chatterjee, Ben George, Ram H. Datar and Donald G. Skinner and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Urology.

In The Last Decade

Peter J. Goebell

58 papers receiving 1.2k citations

Peers

Peter J. Goebell
Monika Joshi United States
Ilaria Lucca Switzerland
Oliver Patschan Sweden
Giovanni Casetta Italy
Beat Foerster Austria
Bernadett Szabados United Kingdom
Andrew von Eschenbach United States
Yoshihiro Tatsumi Japan
Donald W. W. Newling Netherlands
Hussein Khaled Egypt
Monika Joshi United States
Peter J. Goebell
Citations per year, relative to Peter J. Goebell Peter J. Goebell (= 1×) peers Monika Joshi

Countries citing papers authored by Peter J. Goebell

Since Specialization
Citations

This map shows the geographic impact of Peter J. Goebell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Goebell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Goebell more than expected).

Fields of papers citing papers by Peter J. Goebell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Goebell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Goebell. The network helps show where Peter J. Goebell may publish in the future.

Co-authorship network of co-authors of Peter J. Goebell

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Goebell. A scholar is included among the top collaborators of Peter J. Goebell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Goebell. Peter J. Goebell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goebell, Peter J., Ellen E. Paxinos, Jack Chen, et al.. (2024). Potential of an mRNA-Based Urine Assay (Xpert® Bladder Cancer Detection1) in Hematuria Patients - Results from a Cohort Study. Bladder Cancer. 10(1). 25–33.
2.
Hensley, Patrick J., Roland Seiler, Harry W. Herr, et al.. (2023). Bladder preservation after neoadjuvant therapy – 2021 IBCN updates part 1. Urologic Oncology Seminars and Original Investigations. 41(7). 307–312. 1 indexed citations
3.
Ingersoll, Molly A., David C. Müller, Tahlita C.M. Zuiverloon, et al.. (2022). Biology of BCG response in non-muscle invasive bladder cancer - 2021 IBCN Updates Part III. Urologic Oncology Seminars and Original Investigations. 41(5). 211–218. 3 indexed citations
4.
Dyrskjøt, Lars, Antonia Vlahou, Peter C. Black, et al.. (2022). 25 years International Bladder Cancer Network (IBCN): The past, the present, and the future. Urologic Oncology Seminars and Original Investigations. 41(7). 302–306. 1 indexed citations
5.
Hennenlotter, Jörg, Tilman Todenhöfer, Arnulf Stenzl, et al.. (2022). Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria. Urologic Oncology Seminars and Original Investigations. 41(5). 254.e1–254.e8. 1 indexed citations
6.
Wang, Gang, Peter C. Black, Peter J. Goebell, et al.. (2021). Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urologic Oncology Seminars and Original Investigations. 39(5). 301.e17–301.e28. 7 indexed citations
7.
Goebell, Peter J., et al.. (2021). Was machen Urologen in der Praxis?. Der Urologe. 60(6). 760–768. 2 indexed citations
8.
9.
Goebell, Peter J., et al.. (2017). Prognostic factors for overall survival of patients with advanced renal cell carcinoma – data from the German prospective RCC-Registry. Annals of Oncology. 28. v320–v320. 1 indexed citations
10.
Pan, Qi, Anuja Sathe, Peter C. Black, et al.. (2017). CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer. 3(2). 79–88. 21 indexed citations
11.
Sikic, Danijel, Bastian Keck, Sven Wach, et al.. (2017). Immunohistochemiocal subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis. PLoS ONE. 12(6). e0179602–e0179602. 21 indexed citations
12.
13.
Schmitz‐Dräger, Bernd J., Tahlita C.M. Zuiverloon, Ellen C. Zwarthoff, et al.. (2016). Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines. Urologic Oncology Seminars and Original Investigations. 34(10). 437–451. 21 indexed citations
14.
Hammon, Matthias, Michael Uder, Johannes Huber, et al.. (2015). Operative Therapie von Wirbelsäulenmetastasen urologischer Tumoren. Der Urologe. 55(2). 232–240. 2 indexed citations
15.
Rhijn, Bas W.G. van, James W.F. Catto, Peter J. Goebell, et al.. (2014). Molecular markers for urothelial bladder cancer prognosis: Toward implementation in clinical practice. Urologic Oncology Seminars and Original Investigations. 32(7). 1078–1087. 39 indexed citations
16.
Goebell, Peter J., et al.. (2008). Multimodale Therapien zum Blasenerhalt bei High-grade-Blasentumoren. Der Urologe. 47(7). 838–845. 7 indexed citations
17.
Chatterjee, Sunanda, Ben George, Peter J. Goebell, et al.. (2004). Hyperphosphorylation of pRb: a mechanism for RB tumour suppressor pathway inactivation in bladder cancer. The Journal of Pathology. 203(3). 762–770. 67 indexed citations
18.
Jankevičius, Feliksas, et al.. (2002). p21 and p53 Immunostaining and Survival following Systemic Chemotherapy for Urothelial Cancer. Urologia Internationalis. 69(3). 174–180. 16 indexed citations
19.
Goebell, Peter J., et al.. (2000). p53 Immunohistochemistry as a Prognostic Marker in Bladder Cancer. European Urology. 38(6). 691–700. 98 indexed citations
20.
Goebell, Peter J., et al.. (2000). Cyclin-dependent kinase inhibitor p27KIP1 is expressed preferentially in early stages of urothelial carcinoma. Urology. 56(4). 689–695. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monika Joshi Breakdown of academic impact, for papers by Ilaria Lucca Breakdown of academic impact, for papers by Oliver Patschan Breakdown of academic impact, for papers by Giovanni Casetta Breakdown of academic impact, for papers by Beat Foerster Breakdown of academic impact, for papers by Bernadett Szabados Breakdown of academic impact, for papers by Andrew von Eschenbach Breakdown of academic impact, for papers by Yoshihiro Tatsumi Breakdown of academic impact, for papers by Donald W. W. Newling Breakdown of academic impact, for papers by Hussein Khaled
Rankless by CCL
2026